Misonix (NASDAQ:MSON) and ThermoGenesisHoldingsInc . (NASDAQ:THMO) are both small-cap computer and technology companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, risk, dividends, analyst recommendations and institutional ownership.
Earnings and Valuation
This table compares Misonix and ThermoGenesisHoldingsInc .’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Misonix||$38.85 million||7.87||-$7.39 million||N/A||N/A|
|ThermoGenesisHoldingsInc .||$9.67 million||0.95||-$39.72 million||($3.60)||-0.90|
This table compares Misonix and ThermoGenesisHoldingsInc .’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
28.8% of Misonix shares are owned by institutional investors. Comparatively, 7.3% of ThermoGenesisHoldingsInc . shares are owned by institutional investors. 27.9% of Misonix shares are owned by insiders. Comparatively, 68.9% of ThermoGenesisHoldingsInc . shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Volatility & Risk
Misonix has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, ThermoGenesisHoldingsInc . has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500.
This is a summary of current recommendations and price targets for Misonix and ThermoGenesisHoldingsInc ., as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Misonix currently has a consensus price target of $28.50, indicating a potential upside of 43.22%. ThermoGenesisHoldingsInc . has a consensus price target of $7.50, indicating a potential upside of 132.20%. Given ThermoGenesisHoldingsInc .’s higher probable upside, analysts plainly believe ThermoGenesisHoldingsInc . is more favorable than Misonix.
Misonix beats ThermoGenesisHoldingsInc . on 8 of the 11 factors compared between the two stocks.
Misonix, Inc., together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States, the Americas, Europe, Middle East, Asia Pacific, Africa, and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells. Its products are used in various clinical specialties, such as neurosurgery, orthopedic surgery, plastic surgery, wound care, and maxillo-facial surgical applications. The company sells its products through sales representatives and distributors. Misonix, Inc. was founded in 1959 and is based in Farmingdale, New York.
About ThermoGenesisHoldingsInc .
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for cell-based therapies in the United States, China, rest of Asia, Europe, and internationally. The company operates through two segments, Clinical Development and Device. It offers AutoXpress System, an automated system for the isolation, collection and storage of hematopoietic stem cell concentrates derived from cord blood and peripheral blood; Point-of CareXpress System for the rapid, automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells; CAR-TXpress System that addresses the critical unmet need for chemistry, manufacturing and controls improvement of the emerging CAR-T therapies for cancer patients; BioArchive Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for stem cell samples and clinical products; and manual disposables. The company is also developing autologous stem cell-based therapeutics that address medical needs for applications in the vascular, cardiology, and orthopedic markets. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was founded in 1986 and is headquartered in Rancho Cordova, California.
Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.